Skip to main content
Clinical Trials/IRCT20221231056999N2
IRCT20221231056999N2RecruitingPhase 3

Comparison of Oral versus Injectable Iron Chelation Therapy in Reducing Serum Ferritin Levels in Patients with Transfusion Dependent Thalassemia

DHQ Teaching Hospital0 sites50 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
1 year to 15 years (—)
Sex
All

Inclusion Criteria

  • Presenting with beta thalassemia major (defined as group of hereditary disorders characterized by a genetic deficiency in the synthesis of beta-globin chains in blood causes severe, transfusion-dependent anemia).
  • Patients who are transfusions dependent with serum ferritin level >2000 ng/ml.

Exclusion Criteria

  • Children already taking trial treatment (as per medical record).
  • Children with liver failure (ALT & AST >50IU).
  • Children having anemia (hemoglobin level <10 g/dl)
  • Children who will lose during follow ups.
  • Parents/Guardian refused the participation of their child.
  • Stoppage of medicine due to side effects/compliance.

Investigators

Sponsor
DHQ Teaching Hospital

Similar Trials